


## Rutgers Cancer Institute of New Jersey



# Clinical Trials Connection

*A Cancer Resource for Healthcare Professionals*

May 2015

### [Resources for Physicians](#)

 [Send to a Colleague](#)

 [Join Our Mailing List](#)



**Bruce G. Haffty, MD,** is a professor and chair of the [Department of Radiation Oncology](#) at the Cancer Institute of New Jersey, Robert Wood Johnson Medical School and New Jersey Medical School at Rutgers University. He is also the chief of radiation oncology at Robert Wood Johnson University Hospital in New Brunswick and University Hospital in Newark. Dr. Haffty is involved in the development of clinical trials that investigate novel methods of delivering radiation. He has a particular interest in exploring novel molecular targets that may enhance the effects of radiation, and serves as a co-principal investigator of several national clinical trials.

Contact Dr. Haffty:  
[hafftybg@cinj.rutgers.edu](mailto:hafftybg@cinj.rutgers.edu)  
732-235-5203

## Radiation Oncology Clinical Trials

[View printable version](#)

### Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

The study aims to:

- Establish an improvement in overall survival in recurrent GBM patients receiving bevacizumab and re-irradiation compared with patients receiving bevacizumab alone.
- Estimate and compare the rate of objective response in patients with measurable disease.
- Estimate and compare the six-month progression-free survival rate.
- Estimate and compare progression-free survival.
- Estimate and compare the rate of treatment adverse events.

[Learn more about this trial](#)

### NSABP B-51: Phase III Post-Mastectomy and Post-Lumpectomy before NeoAdjuvant Chemotherapy After NSABP B51

The study aims to:

- Evaluate whether the addition of regional nodal radiation to the chest wall and/or breast radiation will significantly reduce the rate of events for invasive breast cancer recurrence-free interval (IBC-RFI) in patients who present with histologically positive axillary nodes but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.

[Learn more about this trial](#)

## Clinical Trial Spotlight

### Targeted Genomic Analysis of Human Cancers

The purpose of this study is to identify potentially "actionable" genomic alterations in cancers using next-generation sequencing technology, with a focus on rare cancers and cancers for which there is limited standard therapy.

[Learn more](#)

### Other Available Trials

[Breast](#)

[Gastrointestinal/  
Hepatobiliary](#)

[Gynecologic](#)

[Hematologic](#)

[Melanoma](#)

[Pediatric](#)

[Phase I](#)

[Prostate](#)

[Thoracic](#)



A Comprehensive Cancer  
Center Designated by the  
National Cancer Institute

## Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer

The study aims to:

- Assess whether patients with unresectable local-regionally advanced NSCLC treated with targeted agents based on molecular characteristics have a longer progression-free survival than those treated with standard care therapy alone.
- Evaluate response rate.
- Assess toxicity.
- Assess overall survival.

[Learn more about this trial](#)

## Radiation from Interventional Cardiovascular Procedures and Risk of Breast Cancer

The study aims to:

- Quantitate the exposure to IR delivered to patients in New Jersey who underwent interventional cardiovascular procedures.
- Calculate population based rates of low, moderate, high, and very high effective doses of IR from interventional cardiovascular procedures.
- Describe the specific types of interventional cardiovascular procedures among persons for whom the long-term risks of IR exposure are most relevant.

[Learn more about this trial](#)

## Characterizing the Tumor Initiating Cells in Human Gliomas

The study aims to:

- Establish cell cultures from primary anonymized patient specimens of high-grade gliomas.
- Collect frozen glioma tissue samples and paraffin-embedded glioma tissue samples for gene expression and immunohistochemical analysis.

[Learn more about this trial](#)



As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey offers patients access to treatment options not available at other institutions within



the state. The Cancer Institute currently enrolls approximately 17 percent of all new adult cancer patients and approximately 70 percent of all pediatric cancer patients onto a clinical trial. Enrollment in these studies nationwide is fewer than five percent of all adult cancer patients.

[Learn more](#)

[Forward email](#)

Cancer Institute of New Jersey | Rutgers, The State University of New Jersey | 195 Little Albany St. | New Brunswick | NJ | 08903